Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Arrowhead Pharma (ARWR) PT Raised to $29 at Leerink Partners
June 3, 2024 1:33 PM EDTLeerink Partners analyst Mani Foroohar raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $29.00 (from $27.00) while maintaining a Market Perform rating.... More
Arrowhead Pharmaceuticals (ARWR) Reports Successful Results for Plozasiran from the Phase 3 PALISADE Study
June 3, 2024 7:32 AM EDTArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints,... More
RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)
May 30, 2024 6:13 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $50.00 price target on Arrowhead Pharma (NASDAQ: ARWR)
The analyst comments "We hosted CEO for Boston NDR and he came across as very confident on cardiometabolic (particularly on upcoming FCS data, differentiation to... More
